<DOC>
	<DOC>NCT00736931</DOC>
	<brief_summary>The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam</brief_summary>
	<brief_title>Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam</brief_title>
	<detailed_description />
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Healthy male or female volunteer aged 18 to 50 years inclusive Body Mass Index (BMI) between 18.0 and 30.0 kg/m² inclusive Good physical and mental health status Blood pressure and heart rate within normal range Electrocardiogram and laboratory tests without clinically significant abnormality IQ ≤ 80 as determined by Test of nonverbal intelligence Center for Epidemiological Studies Depression (CESD Scale ≥16, Known allergy/intolerance to pyrrolidinone derivatives Abnormalities on EEG recordings Pregnant, lactating women History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders Use of any hepatic enzymeinducing drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Brivaracetam</keyword>
	<keyword>Cognitive neurophysiological tests (CNT)</keyword>
	<keyword>Neuropsychological assessments</keyword>
</DOC>